Author, year publication (year cost) | Stage | Comparators | Costs | Outcome’s health | Ratio cost/outcome’s health | |||||
---|---|---|---|---|---|---|---|---|---|---|
Original cost | Adjusted to $US PPP [18] | LYG | QALY | ICER €/LYG | ICUR €/QALY | ICER $US PPP/LYG | ICUR $US PPP/QALY | |||
TARE versus TACE | ||||||||||
Rostambeigi, 2014 [20] (2013)a | Monthlyb | OS months | ||||||||
BCLC-A | TACE | $ 2094 | 2347 | 39.5 | ND | TACE versus | ND | TACE versus | ND | |
TARE (I) | $ 1770 | 1311 | 29.7 | ND | $33/LMG | ND | 37/ LMG | ND | ||
Δ − $ 324 | Δ − 363 | Δ 9.8 | [$ 396 LYG]* | [444/LYG]* | ||||||
TARE (II) | $ 2688 | 3013 | 29.7 | ND | $61/LMG | ND | 68/LMG | ND | ||
Δ $ 594 | Δ 666 | Δ 9.8 | [− $ 732 LYG]* | [− 820/LYG]* | ||||||
BCLC-B | TACE | $ 2326 | 2607 | 22.9 | ND | TACE versus | TACE versus | |||
TARE (I) | $ 2789 | 3126 | 16.0 | ND | $67/LMG | ND | 75/LMG | ND | ||
Δ $ 463 | 519 | Δ 6.9 | [− $ 804 LYG]* | [− 901/LYG]* | ||||||
TARE (II) | $ 4240 | 4753 | 16.0 | ND | $277/LMG | ND | 310/LMG | ND | ||
Δ $1914 | 2145 | Δ 6.9 | [− $3324 LYG]* | [− 3726/LYG]* | ||||||
BCLC-C | TACE | $ 2679 | 3003 | 13.3 | ND | TACE versus | TACE versus | |||
TARE (I) | $2652 | 2973 | 17.1 | ND | $7/LMG | ND | 8/LMG | ND | ||
Δ − $27 | Δ − 30 | Δ 3.8 | [Dominant]* | [Dominant]* | ||||||
TARE (II) | $4031 | 4518 | 17.1 | ND | $356/LMG | ND | 399/LMG | ND | ||
Δ $1352 | Δ 1515 | Δ 3.8 | [$ 4272 LYG]* | [− 4788/LYG]* | ||||||
Rostambeigi, 2014 [21] (2013)a | OS months | |||||||||
BCLC-A, BCLC-B, and BCLC-C | TACE | $ 17,000 | 19,055 | BCLC-A: 37 BCLC-B: 22 BCLC-C: 12 | ND | ND | ND | ND | ND | |
TARE | $ 49,000 | 54,924 | BCLC-A: 32 BCLC-B: 18 BCLC-C: 19 | ND | ND | ND | ND | ND | ||
BCLC-C | TARE-TACE | Δ $ 500 | Δ 560 | ND | ND | ND | ND | ND | ||
Manas, 2021 [22]c (2020) | BCLC-A, BCLC-B | TARE (T™) | £ 49,583 | 49,921 | 3.05 | 2.24 | TARE versus | TARE versus | TARE versus | TARE versus |
TACE | £ 37,038 | 37,291 | 2.14 | 1.57 | £ 12,808 | £ 17,279 | 12,291 | 17,397 | ||
DEB-TACE | £ 33,206 | 33,432 | 2.14 | 1.57 | £ 17,059 | £ 23,020 | 17,175 | 23,177 | ||
TAE | £ 37,015 | 37,267 | 2.14 | 1.57 | £ 12,833 | £ 17,300 | 12,921 | 17,418 | ||
Δ 0.91 | Δ 0.67 | WTP (£20.000/QALY): 15.9% (TARE vs. DEB-TACE) to 76.8% (TARE vs. TACE) WTP (£30.000/QALY): 88.6% (TARE vs. DEB-TACE) to 98.7% (TARE vs. TAE) | ||||||||
Rognoni, 2018 [23] (2016) | BCLC-B | TTS (47% sorafenib) | € 36,509 | 37,137 | 3.494 | 1.385 | – | TTS Dominant | ||
TS | € 42,812 | 43,591 | 2.361 | 0.937 | ||||||
Δ − € 6303 | Δ − 6418 | Δ − 1.133 | Δ 0.448 | TTS WTP (€50,000/QALY): 83% | ||||||
TARE versus TKI | ||||||||||
Chaplin, 2015 [24] (2015)a | BCLC-C | TARE (T™) | £ 21,441 | 22,763 | ND | 1.12 | ND | TARE Dominant | ND | TARE Dominant |
Sorafenib | £ 34,050 | 36,150 | ND | 0.85 | ND | |||||
Δ − £ 12,609 | Δ − 13,387 | ND | Δ 0.27 | ND | ||||||
TARE versus sorafenib TTP (months): 6.2 versus 4.9 OS (months): 13.8 versus 9.7 | ||||||||||
Palmer, 2017 [25] (2017) | BCLC-C | TARE (S®) | £ 8909 in favour of TARE | 9374 favour of TARE | ND | Δ 0.0079 in favour of TARE | ND | TARE cost-effective | ND | TARE cost-effective |
Sorafenib | ||||||||||
Cost drivers: workup and administrations for TARE and duration of treatment for sorafenib | ||||||||||
Rognoni, 2017 [26] (2015) | BCLC-B | TARE | € 31,071 | 31,644 | 2.531 | 1.178 | TARE versus | TARE versus | TARE versus | TARE versus |
Sorafenib | € 29,289 | 29,829 | 1.575 | 0.638 | 1865 | 3302 | 1899 | 3363 | ||
Δ € 1782 | Δ 1815 | Δ 0.956 | Δ 0.540 | WTP (€38500/QALY): 99.2% | ||||||
BCLC-C | TARE | € 21,961 | 22,366 | 1.445 | 0.639 | ND | TARE Dominant | ND | TARE Dominant | |
Sorafenib | € 30,750 | 31,317 | 1.306 | 0.568 | ||||||
Δ − € 8788 | Δ − 8950 | Δ 0.139 | Δ 0.071 | WTP (€38.500/QALY): 98.2% | ||||||
Parikh, 2018 [27] (2018)a | BCLC-C | Pooled data | Sorafenib versus | Sorafenib versus | ||||||
TARE | $ 61,897 | 65,295 | ND | 0.81 | ND | $ 19,534 | ND | 20,606 | ||
Sorafenib | $ 63,313 | 66,789 | ND | 0.88 | ||||||
Δ − $ 1416 | Δ − 1494 | ND | Δ − 0.07 | |||||||
CT SARAH | Sorafenib versus | Sorafenib versus | ||||||||
TARE | $ 64,805 | 68,363 | ND | 0.78 | TARE versus | TARE versus | ||||
Sorafenib | $ 63,216 | 66,687 | ND | 0.87 | ND | Sorafenib Dominant | ND | Sorafenib Dominant | ||
Δ $ 1589 | Δ 1676 | ND | Δ − 0.09 | |||||||
CT SIRveNIB | Sorafenib versus | Sorafenib versus | ||||||||
TARE | $ 57,473 | 60,628 | ND | 0.84 | ND | $ 107,927 | ND | 113,852 | ||
Sorafenib | $ 63,447 | 66,930 | ND | 0.90 | ||||||
Δ − $ 5974 | Δ − 6302 | ND | Δ − 0.06 | |||||||
Walton, 2020 [28] (2017/2018) | BCLC-B and BCLC-C | Deterministic | ||||||||
TARE (T™) | £ 29,888 | 30,922 | 1.110 | 0.764 | NMB (£) | TARE (T™) versus | NMB (£) | TARE (T™) versus | ||
TARE (S®) | £ 30,107 | 31,148 | 1.110 | 0.764 | − 218 | + Costly | 226 | + Costly | ||
TARE (Q®) | £ 36,503 | 37,766 | 1.110 | 0.764 | − 6614 | + Costly | − 6843 | + Costly | ||
Lenvatinib | £ 30,005 | 31,043 | 1.243 | 0.841 | 97 | 28,728 | 100 | 29,722 | ||
Sorafenib | £ 32,082 | 33,192 | 1.183 | 0.805 | 1090 | 2911 | 1128 | 3012 | ||
Probabilistic | ||||||||||
TARE (T™) | £ 30,014 | 31,052 | 1.111 | 0.765 | NMB (£) | TARE (T™) versus | NMB (£) | TARE (T™) versus | ||
TARE (S®) | £ 30,196 | 31,240 | 1.111 | 0.765 | − 2154 | Dominated | − 2229 | Dominated | ||
TARE (Q®) | £ 36,613 | 37,879 | 1.111 | 0.765 | − 2323 | Dominated | − 2403 | Dominated | ||
Lenvatinib | £ 29,658 | 30,684 | 1.244 | 0.841 | − 2306 | 174,320 | − 2386 | 180,349 | ||
Sorafenib | £ 32,444 | 33,566 | 1.202 | 0.825 | − 8741 | Dominated | − 9043 | Dominated | ||
Muszbek, 2020–21 [29]d (2018/2019) | BCLC-B and BCLC-C | TARE (S®) | £ 29,530 | 30,085 | 2.637 | 1.982 | TARE Dominant | TARE Dominant | ||
Sorafenib | £ 30,957 | 31,539 | 1.890 | 1.381 | ND | − £ 2374 | ND | −2719 | ||
Δ − £ 1427 | Δ − 1454 | Δ 0.748 | Δ 0.601 | TARE (S®) WTP (£ 20,000): 95%. INB (£) at threshold of £20,000: £ 13,443 | ||||||
Marqueen, 2021 [30] (2016/2017) | BCLC-C | Pooled data | ||||||||
Sorafenib | $ 78,859 | 84,868 | 0.88 | Sorafenib versus | Sorafenib versus | |||||
TARE | $ 58,397 | 62,847 | 0.87 | ND | $ 1,280,224 | ND | 1,377,777 | |||
Δ $20,462 | Δ 22,061 | Δ 0.02 | Sorafenib WTP ($200,000/QALY): 1% | |||||||
CT SARAH | ||||||||||
Sorafenib | $ 72,899 | 78,454 | 0.83 | Sorafenib versus | Sorafenib versus | |||||
TARE | $ 66,800 | 71,890 | 0.84 | ND | TARE dominant | ND | TARE dominant | |||
Δ $ 6099 | Δ 6564 | Δ − 0.01 | ||||||||
CT SIRveNIB | ||||||||||
Sorafenib | $ 89,806 | 96,649 | 0.91 | Sorafenib versus | Sorafenib versus | |||||
TARE | $ 46,151 | 49,668 | 0.86 | ND | $ 753,412 | ND | 810,822 | |||
Δ $43,655 | Δ 46,982 | Δ 0.06 |